Last reviewed · How we verify

RYZNEUTA — Competitive Intelligence Brief

RYZNEUTA (EFBEMALENOGRASTIM ALFA-VUXW) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Leukocyte Growth Factor [EPC]. Area: Other.

marketed Leukocyte Growth Factor [EPC] specific cell surface receptors Other Live · refreshed every 30 min

Target snapshot

RYZNEUTA (EFBEMALENOGRASTIM ALFA-VUXW) — EVIVE BIOTECHNOLOGY. Efbemalenograstim alfa-vuxw binds to specific cell surface receptors on hematopoietic cells, stimulating their proliferation, differentiation, and functional activation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
RYZNEUTA TARGET EFBEMALENOGRASTIM ALFA-VUXW EVIVE BIOTECHNOLOGY marketed Leukocyte Growth Factor [EPC] specific cell surface receptors
FILGRASTIM FILGRASTIM marketed Leukocyte Growth Factor [EPC] Specific cell surface receptors on hematopoietic cells 1991-01-01
FYLNETRA PEGFILGRASTIM-PBBK KASHIV BIOSCIENCES LLC marketed Leukocyte Growth Factor [EPC] specific cell surface receptors
NYPOZI FILGRASTIM-TXID TANVEX BIOPHARMA USA INC marketed Leukocyte Growth Factor [EPC] Specific cell surface receptors on hematopoietic cells
Rolvedon EFLAPEGRASTIM Spectrum Pharms marketed Leukocyte Growth Factor [EPC] Granulocyte colony-stimulating factor receptor 2022-01-01
Neulasta PEGFILGRASTIM Amgen marketed Leukocyte Growth Factor [EPC] Granulocyte colony-stimulating factor receptor 2002-01-01
Leukine SARGRAMOSTIM Berlex Labs marketed Leukocyte Growth Factor [EPC] Granulocyte macrophage colony-stimulating factor receptor 1991-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Leukocyte Growth Factor [EPC] class)

  1. KASHIV BIOSCIENCES LLC · 2 drugs in this class
  2. Amgen · 1 drug in this class
  3. Berlex Labs · 1 drug in this class
  4. EVIVE BIOTECHNOLOGY · 1 drug in this class
  5. FRESENIUS KABI USA · 1 drug in this class
  6. LUPIN LTD · 1 drug in this class
  7. MYLAN GMBH · 1 drug in this class
  8. SANDOZ INC · 1 drug in this class
  9. SPECTRUM PHARMS · 1 drug in this class
  10. Spectrum Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RYZNEUTA — Competitive Intelligence Brief. https://druglandscape.com/ci/efbemalenograstim-alfa-vuxw. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing